JP2018519324A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018519324A5 JP2018519324A5 JP2017568190A JP2017568190A JP2018519324A5 JP 2018519324 A5 JP2018519324 A5 JP 2018519324A5 JP 2017568190 A JP2017568190 A JP 2017568190A JP 2017568190 A JP2017568190 A JP 2017568190A JP 2018519324 A5 JP2018519324 A5 JP 2018519324A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- item
- composition
- enantiomer
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 41
- 239000003795 chemical substances by application Substances 0.000 claims description 27
- 206010028980 Neoplasm Diseases 0.000 claims description 23
- 201000011510 cancer Diseases 0.000 claims description 23
- 241000124008 Mammalia Species 0.000 claims description 18
- 150000001875 compounds Chemical class 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 15
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 13
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 13
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 13
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 13
- 206010009944 Colon cancer Diseases 0.000 claims description 12
- 241001465754 Metazoa Species 0.000 claims description 12
- 208000029742 colonic neoplasm Diseases 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 201000006402 rhabdoid cancer Diseases 0.000 claims description 12
- 206010005003 Bladder cancer Diseases 0.000 claims description 10
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 10
- 206010025323 Lymphomas Diseases 0.000 claims description 10
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 10
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 208000035475 disorder Diseases 0.000 claims description 10
- 201000005202 lung cancer Diseases 0.000 claims description 10
- 208000020816 lung neoplasm Diseases 0.000 claims description 10
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 10
- 201000002528 pancreatic cancer Diseases 0.000 claims description 10
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 10
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 10
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 6
- 206010014733 Endometrial cancer Diseases 0.000 claims description 6
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 6
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 6
- 208000034578 Multiple myelomas Diseases 0.000 claims description 6
- 206010029260 Neuroblastoma Diseases 0.000 claims description 6
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 6
- 206010033128 Ovarian cancer Diseases 0.000 claims description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 6
- 241000288906 Primates Species 0.000 claims description 6
- 206010060862 Prostate cancer Diseases 0.000 claims description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 6
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 6
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 6
- 208000008938 Rhabdoid tumor Diseases 0.000 claims description 6
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 6
- 208000006593 Urologic Neoplasms Diseases 0.000 claims description 6
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 6
- 201000010881 cervical cancer Diseases 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 6
- 201000004101 esophageal cancer Diseases 0.000 claims description 6
- 206010017758 gastric cancer Diseases 0.000 claims description 6
- 208000005017 glioblastoma Diseases 0.000 claims description 6
- 201000010536 head and neck cancer Diseases 0.000 claims description 6
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 6
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 6
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 6
- 208000032839 leukemia Diseases 0.000 claims description 6
- 201000001441 melanoma Diseases 0.000 claims description 6
- 201000002120 neuroendocrine carcinoma Diseases 0.000 claims description 6
- 206010038038 rectal cancer Diseases 0.000 claims description 6
- 201000001275 rectum cancer Diseases 0.000 claims description 6
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims description 6
- 201000011549 stomach cancer Diseases 0.000 claims description 6
- 229940125565 BMS-986016 Drugs 0.000 claims description 4
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 4
- FBKMWOJEPMPVTQ-UHFFFAOYSA-N N'-(3-bromo-4-fluorophenyl)-N-hydroxy-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole-3-carboximidamide Chemical compound NS(=O)(=O)NCCNC1=NON=C1C(=NO)NC1=CC=C(F)C(Br)=C1 FBKMWOJEPMPVTQ-UHFFFAOYSA-N 0.000 claims description 4
- YGACXVRLDHEXKY-WXRXAMBDSA-N O[C@H](C[C@H]1c2c(cccc2F)-c2cncn12)[C@H]1CC[C@H](O)CC1 Chemical compound O[C@H](C[C@H]1c2c(cccc2F)-c2cncn12)[C@H]1CC[C@H](O)CC1 YGACXVRLDHEXKY-WXRXAMBDSA-N 0.000 claims description 4
- 229950009791 durvalumab Drugs 0.000 claims description 4
- 229960005386 ipilimumab Drugs 0.000 claims description 4
- 229950007699 mogamulizumab Drugs 0.000 claims description 4
- 229960003301 nivolumab Drugs 0.000 claims description 4
- 229960002621 pembrolizumab Drugs 0.000 claims description 4
- 229940055760 yervoy Drugs 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 description 33
- 229940079593 drug Drugs 0.000 description 8
- 241000282412 Homo Species 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 0 CC(C)(c1nc(-c2cncc(C(C(F)(F)F)O)c2)cc(C)c11)N(c2c[n](CC(F)F)nc2)*1=O Chemical compound CC(C)(c1nc(-c2cncc(C(C(F)(F)F)O)c2)cc(C)c11)N(c2c[n](CC(F)F)nc2)*1=O 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562186157P | 2015-06-29 | 2015-06-29 | |
| US62/186,157 | 2015-06-29 | ||
| PCT/US2016/039885 WO2017004079A1 (en) | 2015-06-29 | 2016-06-28 | Lpt-723 and immune checkpoint inhibitor combinations and methods of treatment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020152003A Division JP7054547B2 (ja) | 2015-06-29 | 2020-09-10 | Ｌｐｔ－７２３と免疫チェックポイント阻害剤との組み合わせおよび処置の方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018519324A JP2018519324A (ja) | 2018-07-19 |
| JP2018519324A5 true JP2018519324A5 (enExample) | 2019-08-08 |
| JP6786529B2 JP6786529B2 (ja) | 2020-11-18 |
Family
ID=57609068
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017568190A Expired - Fee Related JP6786529B2 (ja) | 2015-06-29 | 2016-06-28 | Ｌｐｔ−７２３と免疫チェックポイント阻害剤との組み合わせおよび処置の方法 |
| JP2020152003A Expired - Fee Related JP7054547B2 (ja) | 2015-06-29 | 2020-09-10 | Ｌｐｔ－７２３と免疫チェックポイント阻害剤との組み合わせおよび処置の方法 |
| JP2022007869A Ceased JP2022058714A (ja) | 2015-06-29 | 2022-01-21 | Ｌｐｔ－７２３と免疫チェックポイント阻害剤との組み合わせおよび処置の方法 |
| JP2023103633A Pending JP2023120391A (ja) | 2015-06-29 | 2023-06-23 | Ｌｐｔ－７２３と免疫チェックポイント阻害剤との組み合わせおよび処置の方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020152003A Expired - Fee Related JP7054547B2 (ja) | 2015-06-29 | 2020-09-10 | Ｌｐｔ－７２３と免疫チェックポイント阻害剤との組み合わせおよび処置の方法 |
| JP2022007869A Ceased JP2022058714A (ja) | 2015-06-29 | 2022-01-21 | Ｌｐｔ－７２３と免疫チェックポイント阻害剤との組み合わせおよび処置の方法 |
| JP2023103633A Pending JP2023120391A (ja) | 2015-06-29 | 2023-06-23 | Ｌｐｔ－７２３と免疫チェックポイント阻害剤との組み合わせおよび処置の方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (4) | US9861621B2 (enExample) |
| EP (1) | EP3313186A4 (enExample) |
| JP (4) | JP6786529B2 (enExample) |
| HK (1) | HK1254954A1 (enExample) |
| WO (1) | WO2017004079A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201322725D0 (en) | 2013-12-20 | 2014-02-05 | Immodulon Therapeutics Ltd | Cancer therapy |
| EP3313186A4 (en) * | 2015-06-29 | 2019-04-03 | Biomed Valley Discoveries, Inc. | LPT-723 AND IMMUNE CONTROL POINT COMBINATIONS AND TREATMENT PROCEDURES |
| BR112020000719A2 (pt) * | 2017-07-11 | 2020-07-14 | Compass Therapeutics Llc | anticorpos agonistas que ligam o cd137 humano e seus usos |
| US11718679B2 (en) | 2017-10-31 | 2023-08-08 | Compass Therapeutics Llc | CD137 antibodies and PD-1 antagonists and uses thereof |
| WO2019100052A2 (en) | 2017-11-20 | 2019-05-23 | Compass Therapeutics Llc | Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof |
| WO2019139388A1 (ko) * | 2018-01-10 | 2019-07-18 | 보령제약 주식회사 | Pi3 키나아제 억제제 및 면역관문 억제제를 포함하는 암의 예방 또는 치료용 약학적 조성물 |
| US20210299187A1 (en) * | 2018-06-25 | 2021-09-30 | Immodulon Therapeutics Limited | Cancer therapy |
| BR112021008795A2 (pt) | 2018-11-13 | 2021-08-31 | Compass Therapeutics Llc | Construtos de ligação multiespecíficos contra moléculas de ponto de verificação e seus usos |
| US20240009252A1 (en) * | 2020-08-18 | 2024-01-11 | Curators Of The University Of Missouri | Compositions and methods of treatment comprising tumor-targeting bacteria and chemotherapy or immunotherapy agent |
| WO2023091747A1 (en) * | 2021-11-22 | 2023-05-25 | Axial Therapeutics, Inc. | Modulator compounds, pharmaceutical compositions and uses thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US5235033A (en) | 1985-03-15 | 1993-08-10 | Anti-Gene Development Group | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
| FI903489A0 (fi) | 1988-11-11 | 1990-07-10 | Medical Res Council | Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna. |
| US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
| AU3274500A (en) | 1999-03-18 | 2000-10-09 | Exiqon A/S | Detection of mutations in genes by specific lna primers |
| EP2669377A3 (en) | 2003-04-17 | 2015-10-14 | Alnylam Pharmaceuticals Inc. | Modified iRNA agents |
| US20050182005A1 (en) | 2004-02-13 | 2005-08-18 | Tuschl Thomas H. | Anti-microRNA oligonucleotide molecules |
| CN101031658A (zh) | 2004-05-26 | 2007-09-05 | 罗塞塔金诺米克斯有限公司 | 病毒和病毒相关mirna及其用途 |
| WO2006126040A1 (en) | 2005-05-25 | 2006-11-30 | Rosetta Genomics Ltd. | Bacterial and bacterial associated mirnas and uses thereof |
| US9212224B2 (en) * | 2012-05-15 | 2015-12-15 | Bristol-Myers Squibb Company | Antibodies that bind PD-L1 and uses thereof |
| RU2018142605A (ru) * | 2013-09-25 | 2019-02-04 | Вертекс Фармасьютикалз Инкорпорейтед | Селективный ингибитор фосфатидилинозитол-3-киназы-гамма |
| CA2944903A1 (en) * | 2014-04-24 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response |
| US10881732B2 (en) * | 2015-06-01 | 2021-01-05 | Maine Medical Center Research Institute | Enhancing the therapeutic activity of an immune checkpoint inhibitor |
| EP3313186A4 (en) * | 2015-06-29 | 2019-04-03 | Biomed Valley Discoveries, Inc. | LPT-723 AND IMMUNE CONTROL POINT COMBINATIONS AND TREATMENT PROCEDURES |
| DK3858859T3 (da) * | 2015-07-14 | 2025-12-15 | Bristol Myers Squibb Co | Fremgangsmåde til behandling af kræft under anvendelse af en immun checkpointinhibitor; antistof som binder til programmeret død-1 receptor (pd-1) eller programmeret død ligand 1 (pd-l1) |
| JO3620B1 (ar) * | 2015-08-05 | 2020-08-27 | Amgen Res Munich Gmbh | مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم |
| US20170129911A1 (en) * | 2015-11-10 | 2017-05-11 | Massachusetts Institute Of Technology | Complexes comprising a platinum compound and an immune checkpoint inhibitor and related methods |
-
2016
- 2016-06-28 EP EP16818616.1A patent/EP3313186A4/en not_active Withdrawn
- 2016-06-28 WO PCT/US2016/039885 patent/WO2017004079A1/en not_active Ceased
- 2016-06-28 JP JP2017568190A patent/JP6786529B2/ja not_active Expired - Fee Related
- 2016-06-28 HK HK18114058.0A patent/HK1254954A1/zh unknown
- 2016-06-28 US US15/195,723 patent/US9861621B2/en not_active Expired - Fee Related
-
2017
- 2017-11-10 US US15/809,759 patent/US10485796B2/en active Active
-
2019
- 2019-11-22 US US16/692,560 patent/US10716782B2/en not_active Expired - Fee Related
-
2020
- 2020-06-29 US US16/915,562 patent/US11033537B2/en not_active Expired - Fee Related
- 2020-09-10 JP JP2020152003A patent/JP7054547B2/ja not_active Expired - Fee Related
-
2022
- 2022-01-21 JP JP2022007869A patent/JP2022058714A/ja not_active Ceased
-
2023
- 2023-06-23 JP JP2023103633A patent/JP2023120391A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018519324A5 (enExample) | ||
| CL2018001371A1 (es) | Uso de un inhibidor de b-raf y de un inhibidor de mek 1/2 para el tratamiento de un paciente que padece melanoma (divisional solicitud 201502807) | |
| US20190160069A1 (en) | Pharmaceutical combinations | |
| EP4161511A1 (en) | Novel small molecules for targeted degradation of untargetable kras in cancer therapy | |
| JP2017502017A5 (enExample) | ||
| JP2019506403A5 (enExample) | ||
| CA3057969A1 (en) | Combination therapy | |
| KR20170058432A (ko) | 상승 효과적 아우리스타틴 조합 | |
| JP2017530984A5 (enExample) | ||
| JP2017529382A5 (enExample) | ||
| JP2017500320A5 (enExample) | ||
| JP2017510579A5 (enExample) | ||
| JP2018534311A5 (enExample) | ||
| JP2025185043A (ja) | 癌を治療するための免疫調節剤と組み合わせた低酸素活性化型プロドラッグの投与 | |
| JP2017160178A5 (enExample) | ||
| JP2014511383A5 (enExample) | ||
| US12116363B2 (en) | Combinations for immune-modulation in cancer treatment | |
| JP2017502016A5 (enExample) | ||
| JP2020523354A5 (enExample) | ||
| JP2019530706A5 (enExample) | ||
| WO2022007745A1 (zh) | 西奥罗尼及其联合用药治疗非霍奇金淋巴瘤的用途 | |
| HRP20190211T1 (hr) | Inhibitor proteina za prijenos kolesterilestera (cetp) i farmaceutski pripravci koji sadrže spomenuti inhibitor za primjenu u liječenju ili prevenciji kardiovaskularnih bolesti | |
| JP2018511642A5 (enExample) | ||
| JP2018521962A5 (enExample) | ||
| Anandappa et al. | Emerging novel therapeutic agents in the treatment of patients with gastroesophageal and gastric adenocarcinoma |